Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Novel insights into the development and maintenance of the blood-brain barrier.
Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients.
Erratum to: Genomic Binding Sites and Biological Effects of the Vitamin D-VDR Complex in Multiple Sclerosis.
Statins as immunomodulators: comparison with interferon-beta 1b in MS.
An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device.
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
Vestibular-evoked myogenic potentials, clinical evaluation, and imaging findings in multiple sclerosis.
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease.
Evoked potentials in multiple sclerosis.
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Seizure Drug May Help in MS Eye Disease
Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.
Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis; From the Safety Assessment of Biologic ThERapy (SABER) Study.
[Understanding needs of people with Multiple Sclerosis. Perspective of patients and significant others in the German-speaking part of Switzerland].
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Teriflunomide for oral therapy in multiple sclerosis.
From genes to characteristics of multiple sclerosis.
Drug therapy for multiple sclerosis.
Neural correlates of alerting and orienting impairment in multiple sclerosis patients.
Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand.
A case of Guillain-Barré syndrome with meningeal irritation.
A prospective cohort study of vitamin D in optic neuritis recovery.
Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis
Heat sensitive persons with multiple sclerosis are more tolerant to resistance exercise than to endurance exercise.
Pages
« first
‹ previous
…
278
279
280
281
282
283
284
285
286
…
next ›
last »